{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:35:12Z","timestamp":1783402512170,"version":"3.54.6"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.yebeh.2018.06.033","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T09:24:14Z","timestamp":1530696254000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics"],"prefix":"10.1016","volume":"85","author":[{"given":"Kuang-Lin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jainn-Jim","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Liang","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Cheng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ying","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew-Na","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Shyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.06.033_bb0005","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00381-017-3694-5","article-title":"Early vagal nerve stimulator implantation in children: personal experience and review of the literature","volume":"34","author":"Soleman","year":"2018","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrneurol.2016.98","article-title":"Cognitive and neurodevelopmental comorbidities in paediatric epilepsy","volume":"12","author":"Nickels","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.0013-9580.2005.03504.x","article-title":"Cognitive function in preschool children after epilepsy surgery: rationale for early intervention","volume":"46","author":"Freitag","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.31887\/DCNS.2013.15.1\/jhenley","article-title":"AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging","volume":"15","author":"Henley","year":"2013","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.neuron.2009.01.015","article-title":"Synaptic AMPA receptor plasticity and behavior","volume":"61","author":"Kessels","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0896-6273(93)90240-R","article-title":"AMPA receptor activation potentiates zinc neurotoxicity","volume":"10","author":"Weiss","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1523\/JNEUROSCI.16-01-00200.1996","article-title":"AMPA receptor activation is rapidly toxic to cortical astrocytes when desensitization is blocked","volume":"16","author":"David","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0045","doi-asserted-by":"crossref","first-page":"18784","DOI":"10.1073\/pnas.0708970104","article-title":"AMPA receptors and stargazin-like transmembrane AMPA receptor-regulatory proteins mediate hippocampal kainate neurotoxicity","volume":"104","author":"Tomita","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0050","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1111\/epi.13700","article-title":"Ca2+-permeable AMPA receptors associated with epileptogenesis of hypothalamic hamartoma","volume":"58","author":"Kitaura","year":"2017","journal-title":"Epilepsia"},{"issue":"11 Suppl. 8","key":"10.1016\/j.yebeh.2018.06.033_bb0055","first-page":"S14","article-title":"The role of glutamate in epilepsy and other CNS disorders","volume":"44","author":"Meldrum","year":"1994","journal-title":"Neurology"},{"issue":"Suppl. 197","key":"10.1016\/j.yebeh.2018.06.033_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ane.12099","article-title":"AMPA receptors as a molecular target in epilepsy therapy","volume":"127","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0065","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1093\/brain\/awr202","article-title":"Interictal-like network activity and receptor expression in the epileptic human lateral amygdala","volume":"134","author":"Graebenitz","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0070","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1523\/JNEUROSCI.3904-03.2004","article-title":"Enhanced relative expression of glutamate receptor 1 flip AMPA receptor subunits in hippocampal astrocytes of epilepsy patients with Ammon's horn sclerosis","volume":"24","author":"Seifert","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0075","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1126\/science.1699275","article-title":"Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS","volume":"249","author":"Sommer","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0006-8993(00)02951-6","article-title":"The AMPAR subunit GluR2: still front and center-stage1","volume":"886","author":"Tanaka","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.conb.2006.05.004","article-title":"Calcium-permeable AMPA channels in neurodegenerative disease and ischemia","volume":"16","author":"Kwak","year":"2006","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171538","article-title":"AMPA GluA1-flip targeted oligonucleotide therapy reduces neonatal seizures and hyperexcitability","volume":"12","author":"Lykens","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0095","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40263-012-0021-2","article-title":"Perampanel: as adjunctive therapy in patients with partial-onset seizures","volume":"26","author":"Plosker","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic\u2013clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpn.2015.02.008","article-title":"Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study","volume":"19","author":"Rosenfeld","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0120","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0125","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0883073817709195","article-title":"Clinical experience with perampanel for refractory pediatric epilepsy in one Canadian center","volume":"32","author":"Datta","year":"2017","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dmcn.13362","article-title":"Tolerability and efficacy of perampanel in children with refractory epilepsy","volume":"59","author":"Heyman","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2016.08.021","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies\u2014an Italian observational multicenter study","volume":"127","author":"De Liso","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1546276","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences","volume":"46","author":"Bir\u00f3","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2017.05.036","article-title":"Use of perampanel in children and adolescents with Lennox\u2013Gastaut syndrome","volume":"74","author":"Auvin","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2017.08.014","article-title":"Effectiveness and tolerability of perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study","volume":"52","author":"Swiderska","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0160","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0165","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration\u2013effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eplepsyres.2015.11.014","article-title":"Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: a phase III post-hoc analysis","volume":"119","author":"Glauser","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1756285616661115","article-title":"Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data","volume":"9","author":"Rohracher","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0180","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","article-title":"Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy","volume":"54","author":"Brodie","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1684\/epd.2016.0824","article-title":"One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability","volume":"18","author":"Garamendi-Ruiz","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0190","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yebeh.2016.06.005","article-title":"Adjunctive perampanel in refractory epilepsy: experience at tertiary epilepsy care center in Tours","volume":"61","author":"Maurousset","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0195","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","article-title":"Treatment strategies for Dravet syndrome","volume":"32","author":"Knupp","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0200","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1517\/14656566.2015.1084504","article-title":"Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis","volume":"16","author":"Palleria","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2018.06.033_bb0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018304104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018304104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T22:02:51Z","timestamp":1604527371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018304104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":41,"alternative-id":["S1525505018304104"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.06.033","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}